Docetaxel Combined With Cisplatin for Metastatic Extramammary Paget Disease |
| |
| Authors: | Hongzhou Cai Weizhang Xu Bin Yu Xiao Li Liangjun Zhu Zicheng Xu Jin Zhou Yuxiao Zheng Qing Zou Yun Zeng Xinwei Wang Ting Xu |
| |
| Affiliation: | 1. Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China;2. Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China;3. Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China |
| |
| Abstract: | IntroductionMetastatic extramammary Paget disease (EMPD) as a rare intraepithelial carcinoma is fatal. However, no standardized chemotherapy has been established. We provided docetaxel combined with cisplatin to EMPD patients.Patients and MethodsA total of 8 patients with metastatic EMPD were included in this study between July 2010 and July 2015 (mean age, 64.4 years); they underwent a mean of 9.4 cycles of chemotherapy. All the patients were treated with chemotherapy (docetaxel 60 mg/m2 on day 1; cisplatin 25 mg/m2 on days 1-3) as first-line treatment for > 6 cycle (at least 21 days per cycle). Data on tumor response, time to progression, overall survival, and adverse events were collected.ResultsAfter 2 cycles of chemotherapy, 4 patients experienced partial remission and 4 stable disease. The mean overall survival was 28.9 months, and the mean progression-free survival was 9.9 months.ConclusionDocetaxel combined with cisplatin might be a treatment option for metastatic EMPD, with high disease control rate and good overall survival. |
| |
| Keywords: | Chemotherapy Cisplatin Docetaxel Extramammary Paget's disease Metastatic |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
